Introduction: Anthracyclines are among the most powerful antineoplastic drugs ever developed and, even today, they are widely used according to various association schemes in the onco-hematological field. However, cardiotoxicity remains one of the most feared and characteristic side effects, both short and long term, often causing the premature interruption of therapy or irreversible effects after their suspension. In this article, we want to explain the underlying biological mechanisms, the clinical presentation characteristics and the possible strategies to prevent it. Materials and Methods: A computerized research was carried out for the articles to be inserted through use of international databases PUBMED, RESEARCHGATE and GOOGLE SCHOLAR, by typing in keywords such as “anthracyclines cardiotoxicity” and “cardioprotection strategies for anthracycline toxicity” and related articles. Discussion and Conclusions: The toxicity of these drugs on the heart represents the limiting factor both for their indications and for the success of the therapy, sometimes being the cause of premature interruption or impossibility of use in some patients. It depends especially on the cumulative dose used in the single patient and on the pre- existing risk conditions for the development of these ADRs, both in the short and long term. However, there are strategies that can avoid or reduce the damage, both related to the formulation of the compounds and to the co- administration of other drugs.

Introduction: Therapeutic errors are among the main causes of drug-related problems, in terms of enhanced toxicological or reduced therapeutic effect, and concern all stages of the drug chain, from manufacturing to prescription, dispensing and administration. Everyone, pharmacists and doctors in all settings, should be aware of how to prevent and manage them and which drugs are at greatest risk. In this article we will focus on LASA (look alike/sound alike), on FAR (high-risk drugs) and on the guidelines especially for prevention. Methods: The article is a minireview that was written by research in paper and online on PubMed and Embase. We performed a search of any publications available in these databases between the years 1990 and 2022, using the key words: therapeutic errors, misuse / diversion of drugs, drug poisoning. After a review of the titles and abstracts, the articles chosen were considered relevant in providing evidence of the problem. We also added personal knowledge about the topic of the article and used some paper documents. Discussion and Conclusions: Most of the errors in therapy occur during administration, due to errors in doses, posology or interactions or incorrect manipulations of pharmaceutical forms, and in dispensing, due to incorrect interpretation of the prescription or confusion on the packaging in the case of LASAs. Pharmacists and doctors but also patients themselves should pay attention to the time of prescription and doctors to the drug history not only for interactions but also to avoid making mistakes in patients who take drugs with names or packages similar to the one described above. Moreover, attention must be paid in writing the prescription, in dosage, and pharmaceutical forms. Particular attention should be paid to handling by children and to avoiding any misuse of the medicines themselves.